Bank of America Issues Positive Forecast for Cellebrite DI (NASDAQ:CLBT) Stock Price

Cellebrite DI (NASDAQ:CLBT) had its price target boosted by research analysts at Bank of America from $24.00 to $25.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price indicates a potential upside of 28.24% from the company’s previous close.

Several other brokerages have also weighed in on CLBT. Needham & Company LLC lifted their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, November 7th. Lake Street Capital reduced their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 15th. Finally, Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $23.50.

Cellebrite DI Trading Up 22.1%

Shares of CLBT stock traded up $3.53 during trading hours on Thursday, hitting $19.50. 2,687,707 shares of the company were exchanged, compared to its average volume of 1,636,067. The stock has a market capitalization of $4.67 billion, a price-to-earnings ratio of -25.65, a P/E/G ratio of 3.16 and a beta of 1.28. The firm has a fifty day simple moving average of $17.72 and a 200 day simple moving average of $16.69. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.05). Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm had revenue of $126.03 million for the quarter, compared to the consensus estimate of $122.98 million. During the same period last year, the company posted $0.14 earnings per share. Cellebrite DI’s revenue for the quarter was up 17.9% on a year-over-year basis. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Cellebrite DI will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Financial Management Professionals Inc. purchased a new stake in shares of Cellebrite DI in the 3rd quarter valued at $28,000. CWM LLC grew its stake in shares of Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after buying an additional 720 shares during the last quarter. Signaturefd LLC increased its holdings in shares of Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after buying an additional 819 shares during the period. Assetmark Inc. bought a new stake in shares of Cellebrite DI in the 1st quarter valued at about $33,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Cellebrite DI by 1,998.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after acquiring an additional 1,998 shares during the period. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.